Filter Results:
(4,810)
Show Results For
- All HBS Web
(4,810)
- People (16)
- News (1,876)
- Research (2,344)
- Events (2)
- Multimedia (214)
- Faculty Publications (1,853)
Show Results For
- All HBS Web
(4,810)
- People (16)
- News (1,876)
- Research (2,344)
- Events (2)
- Multimedia (214)
- Faculty Publications (1,853)
- March 2019 (Revised June 2021)
- Case
HelloSelf: Foundation
By: John R. Wells and Benjamin Weinstock
On January 6, 2019, HelloSelf, a London-based “BrainTech” company, founded a year earlier by Charles Wells, soft launched. The proposition was simply to help its members “Be your Best Self.” The company provided its registered members with access to a clinical... View Details
Keywords: Startup; Start-up; Startup Management; Startup Marketing; Startups; Start-ups; BrainTech; Marketing Research; Strategic Decision Making; Strategy Development; Strategy Dynamics; Neuroscience; Cognition; Cognitive Psychology; Health ＆ Wellness; Health Care; Health Care Reform; Health Care Outcomes; Self-awareness; Mental Health; Wellbeing; Wellness; Funding; Equity Financing; Raising Capital; Synergies; Team Building; National Health Insurance; Artificial Intelligence; MVP; Business Startups; Health; Health Care and Treatment; Management; Well-being; Marketing Channels; Decision Making; Strategy; Technology; United Kingdom; London
Wells, John R., and Benjamin Weinstock. "HelloSelf: Foundation." Harvard Business School Case 719-492, March 2019. (Revised June 2021.)
- May 2016
- Case
AbbVie
By: Kevin Schulman, Laura Little, Samyukta Mullangi and Stephen Schleicher
This case focuses on the impact of a novel regulatory pathway, the biosimilars pathway, on the strategy of a major pharmaceutical firm that finds its largest product (60% of revenue) at risk. The case reviews the rationale for the pathway, the emerging biosimilars... View Details
- 16 May 2014
- News
Health cuts ‘wrong way’ to reform system, Harvard expert says
- 01 Dec 2018
- News
Case Study: Your Data, Your Health
otherwise take a decade to diagnose. But NextGen Jane is building more diseases into the pipelines. “There are so many understudied areas in women’s health we could explore,” Tariyal says. Illustration by Marcos Chin The Question: “The... View Details
Keywords: Jen McFarland Flint
- January 2, 2020
- Article
Changes in Quality of Care After Hospital Mergers and Acquisitions
By: Nancy Dean Beaulieu, Leemore S. Dafny, B. E. Landon, Jesse Dalton, Ifedayo Kuye and J. Michael McWilliams
Background: The hospital industry has consolidated substantially during the past two decades and at an accelerated pace since 2010. Multiple studies have shown that hospital mergers have led to higher prices for commercially insured patients, but research about effects... View Details
Beaulieu, Nancy Dean, Leemore S. Dafny, B. E. Landon, Jesse Dalton, Ifedayo Kuye, and J. Michael McWilliams. "Changes in Quality of Care After Hospital Mergers and Acquisitions." New England Journal of Medicine 382, no. 1 (January 2, 2020): 51–59.
- July 2021 (Revised July 2022)
- Case
Brigham & Women's Hospital: Using Patient Reported Outcomes to Improve Breast Cancer Care
By: Robert S. Kaplan, Navraj S. Nagra and Syed S. Shehab
Dr. Andrea Pusic, breast cancer reconstruction surgeon, wants to extend outcomes measurement beyond traditional surgical metrics of infections, complications, and survival rates. The case describes her development of a new mobile phone app, which collects patients’... View Details
Keywords: Health Care and Treatment; Outcome or Result; Cost Management; Activity Based Costing and Management; Mobile and Wireless Technology; Health Testing and Trials; Surveys; Health Industry; Boston
Kaplan, Robert S., Navraj S. Nagra, and Syed S. Shehab. "Brigham & Women's Hospital: Using Patient Reported Outcomes to Improve Breast Cancer Care." Harvard Business School Case 122-010, July 2021. (Revised July 2022.)
- February 1996 (Revised April 2004)
- Case
Eli Lilly and Company: Innovation in Diabetes Care
By: Clayton M. Christensen
Summarizes Eli Lilly's history of innovation in its business, describing how the dimensions along which innovations have been made in the industry have changed. Lilly's innovation strategy has been to pursue ever higher performance products, while others in the... View Details
Keywords: Change; Product; Service Delivery; Product Development; Innovation and Management; Innovation Strategy; Health Care and Treatment; Pharmaceutical Industry
Christensen, Clayton M. "Eli Lilly and Company: Innovation in Diabetes Care." Harvard Business School Case 696-077, February 1996. (Revised April 2004.)
- 01 Feb 1997
- News
Herzlinger on Health Care: Revolution in Evolution
use expensive technology, which many people cite as the reason for high U.S. health-care costs? Actually,the opposite is true: advances in medical technology have made health care cheaper and better - and... View Details
- October–December 2005
- Article
Medicine's Service Challenge: Blending Custom and Standard Care
By: Richard Bohmer
Bohmer, Richard. "Medicine's Service Challenge: Blending Custom and Standard Care." Health Care Management Review 30, no. 4 (October–December 2005): 322–330.
- Web
Organize Care Around Medical Conditions - Institute For Strategy And Competitiveness
HBS ISC Health Care Health Care Value-Based Health Care View Details
- February 1999 (Revised March 2000)
- Case
Beth Israel Deaconess Medical Center: Coordinating Patient Care
External cost pressures are motivating the adoption of case management (CM) at Beth Israel Deaconess Medical Center (BIDMC), but several of the organization's key professional groups are working against it. President and CEO David Dolins must decide whether CM is... View Details
Keywords: Organizational Change and Adaptation; Service Operations; Organizational Culture; Health Care and Treatment; Health Industry; Boston
Gittell, Jody H., Kristin Shu, and Julian Wimbush. "Beth Israel Deaconess Medical Center: Coordinating Patient Care." Harvard Business School Case 899-213, February 1999. (Revised March 2000.)
- 01 Dec 2007
- News
Where Are the Innovators in Health Care?
billion of the excessive costs of U.S. health care while all too many quality measures have worsened. Patients learn — sometimes the hard way — to bring along an assertive, intelligent loved one to protect... View Details
- September 2014 (Revised May 2017)
- Case
Fresno's Social Impact Bond for Asthma
By: John A. Quelch and Margaret L. Rodriguez
In 2014, Social Impact Bonds (SIBs) were quickly gaining popularity as an investment vehicle which joined together private investors and nonprofits to tackle social issues. Although numerous SIB projects and proposals had cropped up across the U.S. following the launch... View Details
Keywords: Social Enterprise; Health Care; Marketing; Bonds; Financing; Asthma; Air Pollution; Air Quality; Chronic Disease; Public Health; Health; Health Care and Treatment; Finance; Health Industry; Health Industry; United States
Quelch, John A., and Margaret L. Rodriguez. "Fresno's Social Impact Bond for Asthma." Harvard Business School Case 515-028, September 2014. (Revised May 2017.)
- 28 Nov 2016
- News
What’s good for employee health is good for the company
- June 2014 (Revised April 2015)
- Supplement
OrthoChoice: Bundled Payments in the County of Stockholm (B)
By: Michael E. Porter, Clifford M. Marks and Zachary C. Landman
By the end of 2008, all major hospitals (one of which was private) and three private specialized orthopedic centers signed OrthoChoice contracts. In 2009, hip and knee replacements in the County of Stockholm for relatively healthy patients began being reimbursed. By... View Details
Keywords: Hip Replacement; Bundled Payment; Knee Replacement; Value Agenda; Strategy; Health Care Industry; Health; Health Care and Treatment; Health Disorders; Health Industry; Sweden
Porter, Michael E., Clifford M. Marks, and Zachary C. Landman. "OrthoChoice: Bundled Payments in the County of Stockholm (B)." Harvard Business School Supplement 714-515, June 2014. (Revised April 2015.)
- March 2014
- Editorial
Limits on Use of Health Economic Assessments for Rare Diseases
By: Hanna I. Hyry, Ariel Dora Stern, Jonathan CP Roos and Timothy M. Cox
Funding of expensive treatments for rare ('orphan') diseases is contentious. These agents fare poorly on 'efficiency' or health economic measures, such as the QALY, because of high cost and frequently poor gains in quality of life and survival. We show that... View Details
Hyry, Hanna I., Ariel Dora Stern, Jonathan CP Roos, and Timothy M. Cox. "Limits on Use of Health Economic Assessments for Rare Diseases." hcu016. QJM: An International Journal of Medicine 107, no. 3 (March 2014): 241–245.
- 15 Dec 2024
- News
Agenda: Amanda E/J Morrison (MBA 2014)
RIPPLE EFFECT “A woman gets a period around age 12 to 14, and then we tell her to go off in the world and not get pregnant.” “A woman gets a period around age 12 to 14, and then we tell her to go off in the world and not get pregnant.” For 15 years, the morning-after... View Details
- October 5, 2017
- Article
Making Patients and Doctors Happier—The Potential of Patient-Reported Outcomes
By: Lisa Rotenstein, Robert S. Huckman and Neil Wagle
Rotenstein, Lisa, Robert S. Huckman, and Neil Wagle. "Making Patients and Doctors Happier—The Potential of Patient-Reported Outcomes." New England Journal of Medicine 377, no. 14 (October 5, 2017): 1309–1312.
- 29 Aug 2016
- News